Trial Profile
Stusy of asunaprevir and daclatasvir in patients with recurrent hepatitis C
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Sep 2018
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 14 Sep 2018 New trial record
- 01 Sep 2018 Results published in the Anticancer Research